Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells

Figure 5 Effect of nicotine on paclitaxel treatment. A: Viability determination of MDA-MB-231 cells treated with nicotine (10^-10 mol/L) and paclitaxel (10^-7 mol/L) alone or in combination, in the absence or presence of nicotinic antagonists: mecamylamine [non-selective for nicotinic acetylcholine receptors (nAChRs)], methyllycaconitine (selective for α7 nAChRs), or luteolin (selective for α9 nAChRs) at a concentration of 10^-6 mol/L; B: Determination of percentage of living MDA-MB-231 cells treated with the same drug combinations as those shown in Figure 5A. Values are the mean ± SD of four experiments performed in duplicate. ^bP < 0.01; ^cP < 0.001 vs control, considered as 100%. MM: Mecamylamine; MLA: Methyllycaconitine; Lut: Luteolin; PX: Paclitaxel; NIC: Nicotine.